Clinical Trial of PLB1003 by Beijing Pearl Biotechnology

As of April 19, 2017 lists a phase 1 trial of PLB1003 which targets ALK. At this time the trial is at one site: Shanghai Chest Hospital.

To qualify you must have one measurable met in the body.

The trial identifier is: NCT03130881.

This entry was posted in Lung cancer, PLB1003 - Beijing Pearl Biotechnology, Potential Treatments, Research. Bookmark the permalink.

Leave a Reply